4.1 Article

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat

Journal

CANCER DRUG RESISTANCE
Volume 4, Issue 4, Pages 888-902

Publisher

OAE PUBLISHING INC
DOI: 10.20517/cdr.2021.44

Keywords

Histone deacetylase; bortezomib resistance; selective HDAC inhibitors; HDAC6; HDAC7

Categories

Funding

  1. Karus Pharmaceuticals
  2. Novartis Pharmaceuticals
  3. National Cancer Institute [R01 CA184464, R01 CA194264]
  4. Leukemia & Lymphoma Society Specialized Center of Research [SCOR-12206-17]
  5. Dr. Miriam and Sheldon G. Adelson Research Foundation

Ask authors/readers for more resources

This study investigated the expression of HDAC family members in bortezomib sensitive vs. resistant myeloma cell lines, with findings showing differential expression of HDAC6 and HDAC7 in these cells. Panobinostat was effective in inducing cell death and modulating HDAC expression in resistant cells. Inhibition of HDAC7 suppressed cell growth, while pharmacological inhibition of HDAC6 enhanced cell death induced by panobinostat, indicating distinct roles for these enzymes in bortezomib resistance.
Aim: Multiple myeloma (MM) is a hematological malignancy of antibody-producing mature B cells or plasma cells. The proteasome inhibitor, bortezomib, was the first-in-class compound to be FDA approved for MM and is frequently utilized in induction therapy. However, bortezomib refractory disease is a major clinical concern, and the efficacy of the pan-histone deacetylase inhibitor (HDACi), panobinostat, in bortezomib refractory disease indicates that HDAC targeting is a viable strategy. Here, we utilized isogenic bortezomib resistant models to profile HDAC expression and define baseline and HDACi-induced expression patterns of individual HDAC family members in sensitive vs. resistant cells to better understanding the potential for targeting these enzymes. Methods: Gene expression of HDAC family members in two sets of isogenic bortezomib sensitive or resistant myeloma cell lines was examined. These cell lines were subsequently treated with HDAC inhibitors: panobinostat or vorinostat, and HDAC expression was evaluated. CRISPR/Cas9 knockdown and pharmacological inhibition of specific HDAC family members were conducted. Results: Interestingly, HDAC6 and HDAC7 were significantly upregulated and downregulated, respectively, in bortezomib-resistant cells. Panobinostat was effective at inducing cell death in these lines and modulated HDAC expression in cell lines and patient samples. Knockdown of HDAC7 inhibited cell growth while pharmacologically inhibiting HDAC6 augmented cell death by panobinostat. Conclusion: Our data revealed heterogeneous expression of individual HDACs in bortezomib sensitive vs. resistant isogenic cell lines and patient samples treated with panobinostat. Cumulatively our findings highlight distinct roles for HDAC6 and HDAC7 in regulating cell death in the context of bortezomib resistance.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available